Daiichi Sankyo takes option on diabetes stem cell start-up

Japan’s Daiichi Sankyo has joined an open innovation research initiative that will try to develop a therapy for type 1 diabetes based on insulin-producing cells.

The drugmaker has teamed up with Tokyo Institute of Technology for the project, which has financial backing from Mitsubishi UFJ Capital.